Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ExtremoChem

Financiado

Cerrado

Chemically synthesised novel compounds for the stabilisation of biologics

Biologics are medical drugs produced using biotechnology, other than direct extraction from a native biological source. Many of biopharmaceutical products are subject to very strict production, storage and distribution requirement... ver más

31/03/2017

EXTREMOCHEM

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

EXTREMOCHEM LDA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-03-31

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

EXTREMOCHEM

50.00K€ | Lider

Proyectos interesantes

RTI2018-096344-B-I00

Medical Technol...

Chemical Engine...

57K€ Cerrado

PIPPI

Medical Technol...

Biotechnology

4M€ Cerrado

SAF2010-20822-C02-01

Medical Technol...

Chemical Engine...

393K€ Cerrado

CTQ2015-68677-R

Medical Technol...

Chemical Engine...

67K€ Cerrado

PRE2020-091826

Medical Technol...

Chemical Engine...

99K€ Cerrado

ESTUDIO SOBRE LA ESTABILIZACIÓN E INACTIVACIÓ...

Medical Technol...

Pharmaceutical...

643K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 3 meses Fecha Inicio: 2016-12-09
Fecha Fin: 2017-03-31

Líder del proyecto

EXTREMOCHEM LDA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Biologics are medical drugs produced using biotechnology, other than direct extraction from a native biological source. Many of biopharmaceutical products are subject to very strict production, storage and distribution requirements in order to preserve effectiveness and safety. Biopharmaceuticals stability is a key issue in assuring that these medicines maintain their quality, safety and full potency. Once potency is lost, it cannot be restored, this means the biologic is wasted. ExtremoChem synthesises a line of novel compounds consisting of synthetic small organic molecules, from 8 to 12 carbons, that are able to stabilise proteins and other biological material by preventing their degradation under stressful conditions, such as higher or lower temperatures, pH, salinity, agitation under which they would otherwise degrade. eXtremochem is suitable for a wide range of proteins such as mAbs, vaccines, insulins, interferins and etc. But ExtremoChem currently focuses on mAbs, such as Humira (for rheumatoid arthritis) & Neupogen (for growth of white blood cells), since they present a high value market. The eXtremochem compounds improve the stability of molecules in the most critical purification stages and protects biologics, preventing aggregation and increasing production volume by 20%. Furthermore, eXtremochem enables long-term storage of thermally sensitive biologics without the need for cold chain, thus bringing significant savings to biopharmaceuticals – 6.5% of their revenues. The Phase 1 project will allow ExtremoChem to evaluate the medicines’ degradation under the presence of the small organic molecules through several stabilization tests, prepare a feasible industrial scale-up plan, plan a sound Ph 1 clinical trial, elaborate the business scale up, and size the reachable market and a reliable market share. Within the overall project, ExtremoChem aims to: obtain the clinical validation and sign at least one commercial agreement.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores